中文别名:
乳酸多韦替尼;多维替尼;丙酸, 2-羟基-, 复合物 4-氨基-5-氟-3-[6-(4-甲基-1-哌嗪基)-1H-苯并咪唑-2-基]-2(1H)-喹啉酮, 水合物 (1:1:1);DOVI锡IB;多韦替尼乳酸盐;多韦替尼多维替尼;4-氨基-5-氟-3-[6-(4-甲基-1-哌嗪基)-1H-苯并咪唑-2-基]-2(1H)-喹啉酮 2-羟基丙酸盐一水物;多韦替尼
英文别名:
4-Amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone 2-hydroxypropanoate hydrate (1:1:1);Unii-69vky8p7ea;Dovitinib lactate(TKI258);Propanoic acid, 2-hydroxy-, coMpd. with 4-aMino-5-fluoro-3-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-2(1H)-quinolinone, hydrate (1:1:1);Propanoic acid, 2-hydroxy-, coMpd. with 4-aMino-5-fluoro-3-[6-(4-Methyl-1-piperazinyl)-1H-benziMidazol-2-yl]-2(1H)-quinolinone, hydrate;Dovitinib(C3H6O3:H20)=1:1:1;Dovitinib lactate Monohydrate;4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydr
InChI:
InChI=1/C21H21FN6O.C3H6O3.H2O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29;1-2(4)3(5)6;/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29);2,4H,1H3,(H,5,6);1H2
产品用途:
多韦替尼是一种口服给药的3期多酪氨酸激酶抑制剂(之前称为TKI258)。OV公司拥有其全球开发和商业化的独占权,正基于来自患者活检和临床结果的现有数据开发多韦替尼的药物应答预测因子(DRP®),计划用于回顾性和前瞻性地甄别现有临床试验中对多韦替尼治疗有应答和无应答的患者。